ActSwiftly Activation and switch of fates in T lymphocytes.
- Coordinator
- Ustav Molekularni Genetiky Av Cr V.v.i., Czechia
- Runs
- 1 January 2025 to 31 December 2029
- Status
- Running
- EU funding
- €2.6m
- Total cost
- €2.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101125695
What the project is doing
In the project's own words, from its summary on CORDIS.
Antigen-stimulated naïve CD8+ T cells proliferate and differentiate into effector and memory cells. Whereas effector T cells remove infected or cancerous cells, memory T cells protect the organism from re-infections. Despite decades of research, the challenging central questions of how naïve T cells form diverse progeny and what drives the differential response of naïve and memory T cells to infection remain unanswered, largely because of lacking experimental tools.
The goal of this project is to generate a comprehensive model of cell-fate choices of naïve and memory CD8+ T cells in vivo. We will achieve this by addressing three complementary specific objectives:1) To understand the early and late fate choices in naïve T cells.2) To uncover differences between naïve and memory T-cell responses and fates.3) To identify the role of proximal protein kinases LCK and FYN in T-cell fate choices.
We will pursue these aims using a combination of experimental immunology and systems biology. We used the synergy between novel genetic models and single cell atlases (i) to characterize an unprecedented transient stage of activated T cells, (ii) to determine the early gene expression signatures and fate choices of in vivo activated naïve and memory T cells, and (iii) to observe that LCK secures memory T-cell formation.
These tools and findings offer us novel perspectives to tackle the challenging objective in its full complexity. We will develop additional unique experimental models coupled with innovative in-silico techniques to uncover the cellular and molecular mechanisms underlying diverse fate choices of particular T-cell subsets and to narrow the gap between mouse and human immunology. Overall, this project has the ambition to resolve long-standing fundamental questions in immunology to open new avenues for targeting and modulating T-cell fates in vivo for efficient vaccine design and for promoting beneficial cytotoxic responses to chronic infections and cancer.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ustav Molekularni Genetiky Av Cr V.v.i. | Praha 4 | Czechia | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI